From GlobeNewswire:

MacroGenics, Inc. will participate in the 42nd Annual J.P. Morgan Healthcare Conference. President & CEO, Scott Koenig, M.D., Ph.D., will provide an overview on Jan. 11 at 7:30 am PT. A webcast of the presentation can be accessed on MacroGenics’ website. The company focuses on developing monoclonal antibody-based therapeutics for cancer treatment from its proprietary technology platforms.

MacroGenics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing monoclonal antibody-based therapeutics for cancer treatment. Their innovative product candidates are generated from their technology platforms, and they have strategic collaborations with global pharmaceutical and biotechnology companies. For more information, visit their website at www.macrogenics.com.



Read more: MacroGenics to Participate in Upcoming Investor Conference